NasdaqGS:ZBIOBiotechs
Zenas BioPharma (ZBIO) Is Down 9.4% After Non-Dilutive Funding And Shelf Filing Update - Has The Bull Case Changed?
In March 2026, Zenas BioPharma reported a wider quarterly and full-year net loss alongside higher revenue, while also securing up to US$250,000,000 in non-dilutive term loan financing and filing a US$78,589,885 shelf registration linked to an ESOP-related common stock offering.
This combination of a larger loss, incremental revenue from partnerships, and substantial new funding reshapes how the company can support obexelimab’s commercialization plans and broader pipeline activities.
With...